Trial Profile
An observational, cohort study of ceftaroline in patients with spinal infections caused by gram-positive pathogens
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2016
Price :
$35
*
At a glance
- Drugs Ceftaroline fosamil (Primary)
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms DISC
- 27 Dec 2016 New trial record
- 30 Oct 2016 Results of preliminary analysis (n=24) presented at the IDWeek 2016.